Pharmaceuticals News and Research

RSS

No doughnut hole in global mail-order pharmacy

Thanks to the Patient Protection and Affordable Care Act signed into law by President Obama on March 23, 2010, Medicare enrollees who enter the dreaded "doughnut hole" -- the Medicare Part D coverage gap that has made seniors responsible for all their drug costs between $2,830 and $6,440 -- will save $250 in 2010. But Betterthanmedicare.com is already saving seniors thousands of dollars, because the global mail-order pharmacy has no doughnut hole.

2 Apr 2010

Cyclacel Pharmaceuticals' abstracts on cell cycle inhibitor drugs selected for presentation at AACR meeting

Cyclacel Pharmaceuticals, Inc. today announced that six abstracts highlighting translational and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC.

2 Apr 2010

Pfizer shares details of financial relationships with U.S. healthcare professionals and researchers

Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.

2 Apr 2010

U.S. Court upholds validity of Eli Lilly's Gemzar compound patent

Eli Lilly and Company today announced that the U.S. District Court for the Southern District of Indiana has upheld the validity of the company's compound patent on Gemzar® (gemcitabine HCl for injection). This decision maintains Lilly's U.S. exclusivity for Gemzar through November 15, 2010.

2 Apr 2010

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

CPEX Pharmaceuticals Inc. today announced that its partner, Serenity Pharmaceuticals, has entered into a global agreement with Allergan, Inc. for the development and commercialization of Ser-120, a product candidate currently in Phase III clinical trials for the treatment of nocturia that utilizes CPEX's patented intranasal drug delivery technology.

2 Apr 2010

Strong demand leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals

IMS Health today reported 5.1 percent growth in 2009 U.S. sales of ethical pharmaceuticals and insulins through retail and non-retail channels, reaching $300.3 billion, compared with growth of 1.8 percent in 2008.

2 Apr 2010

U.S. Court finds Teva Pharmaceutical Industries' Seasonique patent valid and enforceable

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.

2 Apr 2010

Teva Pharmaceutical Industries' Gemzar patent litigation: U.S. court issues decision

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana issued a decision yesterday on two patents for Gemzar® (gemcitabine); the compound patent expiring on November 15, 2010, and a method of use patent expiring on May 7, 2013.

2 Apr 2010

2010 DDW conference to highlight breakthrough research on GI health

Thousands of physicians, researchers and academics from around the world will gather in New Orleans in early May for Digestive Disease Week- (DDW-), the premiere scientific conference in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

2 Apr 2010

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin®.

2 Apr 2010

APP, Fresenius Kabi and sanofi-aventis sign license and settlement agreements

Fresenius Kabi Pharmaceuticals Holding, Inc.,, the parent company of APP Pharmaceuticals, Inc., announced today that APP and other Fresenius Kabi companies have entered into license and settlement agreements with sanofi-aventis covering patents that apply to Eloxatin® (oxaliplatin injection and oxaliplatin for injection).

2 Apr 2010

Biotech reports record financial results for 2010 first quarter

Biotech racked up impressive gains for both the month of March and the first quarter of 2010. The Burrill Biotech Select Index posted a 3.7 percent jump in value in March and an 8 percent overall gain for Q1 '10.

2 Apr 2010

Pfizer discloses $35 million in payments to doctors, hospitals for research and promotion

Pfizer, the largest drug maker in the world, disclosed 35 million in payments during the second half of 2009 to doctors who consulted or spoke on behalf of drugs and to the medical centers that tested them, The New York Times reports. This is Pfizer's first disclosure of this nature. "While other pharmaceutical companies have disclosed payments to doctors, Pfizer is the first to disclose payments for the clinical trials. The disclosure does not include payments outside the United States" (Wilson, 3/31).

2 Apr 2010

Liver function tests misinterpreted in majority of children's hospitals

New research led by physician-scientists at University of California, San Diego School of Medicine shows that the test most commonly used to screen pediatric patients for chronic liver disease is often incorrectly interpreted in many children's hospitals throughout the United States.

2 Apr 2010

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

Santarus, Inc., a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc., the consumer healthcare subsidiary of Merck & Co., Inc., has commenced promotion of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its licensing agreement with Santarus for the over-the-counter (OTC) market in North America. The OTC heartburn market in the U.S. is estimated at approximately $1.8 billion based on data from market research firm Information Resources, Inc. and Santarus estimates.

2 Apr 2010

Protein vaccines for needle-free immunization through the skin

Most immunizations currently involve an injection in the arm. In the future, vaccination may be accomplished without the unpleasant jab of a needle: a team led by Victor C. Yang at the University of Michigan (USA) has developed a method by which vaccines can pass directly through the skin without a needle. As the researchers report in the journal Angewandte Chemie, merely linking a special short peptide molecule to the vaccine, which can then be administered in the form of a patch, will do the job.

1 Apr 2010

Allergan, Serenity Pharmaceuticals announce global agreement for nocturia drug development

Allergan, Inc. and Serenity Pharmaceuticals, LLC today announced a global agreement for the development and commercialization of Ser-120, a Phase III investigational drug currently in clinical development for the treatment of nocturia, a common yet often under-diagnosed urological disorder in adults characterized by frequent urination at night time.

1 Apr 2010

Ricerca Biosciences, Life Science Partner announce business development agreement

Ricerca Biosciences, a preclinical contract research drug development company, is pleased to announce a business development agreement with Life Science Partner (LSP) Co., Ltd., of Tokyo, Japan. Ricerca offers a unique spectrum of services for the areas of agrochemical registration, environmental analysis and pre-investigational new drug (IND) biopharmaceutical registration.

1 Apr 2010

Lotus Pharmaceuticals reports EBIT increase of 29% in 2009

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") reported that its 2009 net earnings were approximately $16.4 million, or $0.33 per diluted share, compared with approximately $12.8 million, or $0.27 per diluted share, in 2008. Net revenues were approximately $57.8 million in 2009 compared with $73.8 million in 2008.

1 Apr 2010

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

ImmunoCellular Therapeutics announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.

1 Apr 2010

Pharmaceuticals News and Research

No doughnut hole in global mail-order pharmacy

Cyclacel Pharmaceuticals' abstracts on cell cycle inhibitor drugs selected for presentation at AACR meeting

Pfizer shares details of financial relationships with U.S. healthcare professionals and researchers

U.S. Court upholds validity of Eli Lilly's Gemzar compound patent

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

Strong demand leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals

U.S. Court finds Teva Pharmaceutical Industries' Seasonique patent valid and enforceable

Teva Pharmaceutical Industries' Gemzar patent litigation: U.S. court issues decision

2010 DDW conference to highlight breakthrough research on GI health

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

APP, Fresenius Kabi and sanofi-aventis sign license and settlement agreements

Biotech reports record financial results for 2010 first quarter

Pfizer discloses $35 million in payments to doctors, hospitals for research and promotion

Liver function tests misinterpreted in majority of children's hospitals

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

Protein vaccines for needle-free immunization through the skin

Allergan, Serenity Pharmaceuticals announce global agreement for nocturia drug development

Ricerca Biosciences, Life Science Partner announce business development agreement

Lotus Pharmaceuticals reports EBIT increase of 29% in 2009

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence